Septerna (NASDAQ:SEPN) Stock Price Target Raised at Guggenheim

Septerna (NASDAQ:SEPN) had its price target raised by Guggenheim from $51.00 to $65.00 in a research report sent to investors on Friday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

SEPN has been the topic of a number of other research reports. JonesTrading increased their target price on Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 13th. HC Wainwright raised their target price on Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. JPMorgan Chase & Co. boosted their price target on Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. Stifel Nicolaus set a $49.00 price target on shares of Septerna in a research report on Tuesday, August 11th. Finally, Wells Fargo & Company increased their price objective on shares of Septerna from $50.00 to $61.00 and gave the stock an “overweight” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $55.22.

Septerna Trading Up 3.2%

NASDAQ:SEPN traded up $1.50 during trading hours on Friday, reaching $48.85. The company had a trading volume of 384,548 shares, compared to its average volume of 378,831. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -90.46 and a beta of 2.20. The firm’s 50 day moving average price is $39.52 and its 200-day moving average price is $32.59. Septerna has a 52 week low of $17.55 and a 52 week high of $51.10.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.14. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. The firm had revenue of $26.75 million for the quarter, compared to analysts’ expectations of $19.22 million. On average, analysts forecast that Septerna will post -1.41 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Daniel Long sold 3,333 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total transaction of $126,087.39. Following the completion of the transaction, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,647,265.96. The trade was a 3.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Elizabeth Bhatt sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total value of $1,100,000.00. Following the transaction, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $7,665,196. This trade represents a 12.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 32,333 shares of company stock worth $1,375,727 in the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Institutional Trading of Septerna

Hedge funds and other institutional investors have recently modified their holdings of the company. TRV GP V LLC purchased a new position in shares of Septerna during the 2nd quarter valued at $208,160,143. TRV GP VI LLC purchased a new stake in Septerna in the 2nd quarter worth $141,048,460. BlackRock Inc. purchased a new stake in Septerna in the 2nd quarter worth $64,706,000. Jupiter Topco LLC purchased a new stake in Septerna in the 2nd quarter worth $43,723,000. Finally, Primecap Management Co. CA bought a new stake in Septerna during the second quarter valued at about $39,096,000.

About Septerna

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company’s research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds.